Jake Jorgovan
NOVEMBER 29, 2023
The Value of a Biopharma Consulting Firm Beyond mere compliance, these consultants offer strategic vision. BioPharma Consultants : Specializes in marketing, strategy, and corporate development services for the biotech and pharmaceutical industries, offering solutions from product launch plans to commercial support for fundraising.
Frost & Sullivan
AUGUST 9, 2021
Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. About Frost & Sullivan.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
IBM Business Partners
AUGUST 7, 2023
Site selection and recruitment challenges are key cost drivers to IBM’s biopharma clients, with estimates, between $15-25 million annually depending on size of the company and pipeline. Additionally, biopharma companies may find themselves building out AI capabilities in-house sporadically and without overarching governance.
Frost & Sullivan
AUGUST 9, 2021
Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. About Frost & Sullivan.
Frost & Sullivan
JANUARY 28, 2021
Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies. Enable screening, diagnoses and the fulfillment of treatments through existing innovation in smart devices , mHealth wearables, apps, and diagnostics.
Frost & Sullivan
APRIL 25, 2023
years, to become a truly global company with a diverse mix of public sector and biopharma clients. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. Christine Dingivan said, “This award recognizes the efforts of everyone who works at Emmes.
IBM Business Partners
JULY 19, 2023
We believe that leveraging generative AI-Automation can drive benefits in life sciences—including in regulated domains—and reduce cycle times for creating AE Narratives by at least 50%, based on work being done by IBM Consulting and the Pharmacovigilance group at a global BioPharma company.
Expert insights. Personalized for you.
130 
Let's personalize your content